Intramuscular botulinum toxin compared to placebo: outcomes at 4–6 and 12–24 weeks | | | |
Pain (0–10 cm VAS or verbal rating scale) | | | |
At 4–6 wks | 4 | 86 | −1.12 (−2.89, 0.66) |
At 12–24 wks | 3 | 66 | −1.22 (−2.37, −0.07)** |
Spasticity on modified Ashworth Scale (0–5; higher = worse) | | | |
At 4–6 wks | 2 | 45 | −0.62 (−1.40, 0.17) |
At 12–24 wks | 2 | 45 | −0.13 (−0.65, 0.38) |
Passive shoulder flexion (0–180; higher = better function) | 1 | | |
At 4–6 wks | 1 | 29 | 3.00 (−15.54, 21.54) |
At 12–24 wks | 1 | 29 | 1.00 (−17.87, 19.87) |
Passive shoulder abduction (0–180; higher = better function) | | | |
At 4–6 wks | 3 | 65 | 8.49 (−2.40, 19.39) |
At 12–24 wks | 2 | 45 | 17.72 (−9.61, 45.04) |
Shoulder external rotation (0–180; higher = better function) | | | |
At 4–6 wks | 3 | 70 | 9.84 (0.20, 19.49)** |
At 12–24 wks | 2 | 50 | 11.86 (−0.61, 24.33) |
No. adverse events | 3 | 65 | 1.46 (0.64, 3.36) |
At 4–6 wks | 1 | 20 | 3.00 (0.37, 24.17) |
At 12–24 wks | 2 | 45 | 0.84 (0.10, 7.10) |
Intramuscular botulinum toxin compared to triamcinolone: outcomes at 12 weeks | | | |
Change in pain on 0–10 numeric rating scale (higher = more pain) | 1 | 29 | 1.70 (−0.08, 3.48) |
Change in physician global rating scale (0–4; 4 = maximum improvement) | 1 | 29 | 0.00 (−0.72, 0.72) |
Change in passive shoulder flexion (0–180; higher = better function) | 1 | 29 | 8.30 (−4.06, 20.66) |
Change in passive shoulder abduction (0–180; higher = better function) | 1 | 29 | 5.60 (−6.05, 17.25) |
Change in passive shoulder external rotation (0–90; higher = better) | 1 | 29 | 7.90 (−5.30, 21.10) |
Change in passive shoulder internal rotation (0–90; higher = better) | 1 | 29 | 9.30 (−0.36, 18.96) |
Change in spasticity on modified Ashworth Scale (0–5; higher = worse) | 1 | 29 | −0.20 (−1.00, 0.60) |